Indeed, a successful eradication of the tumor clone by PPP in the therapeutic setting of the 5TMM in vivo model (61,64,65) set the stage for the use of inhibition of the IGF-1R in MM therapy. This evidence concerns the gene IGF1R and Miyoshi myopathy.